1Y Target$7.50Near-term target
5Y Target$10.86Compound horizon
10Y Target$28.26Long-dated conviction
FCF$989mTTM · 03/26C+FCF $989m — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+11.7%TTM YoYBRevenue +11.7% — at or above S&P median
D/E——D/E data unavailable — neutral default
P/S0.2xAP/S 0.2x — deep value on sales
PEG0.01APEG 0.01 — exceptional; paying well under fair value for growth
Why now
Drug Manufacturers - Specialty & Generic · market cap $2.0b. Down 38% from 52-week high of $8.69 — deep drawdown territory. Revenue growing +12%, comfortably above the S&P median. PEG 0.01 — paying under fair value for the growth rate. 6 sell-side analysts rate this a Hold with a mean 1-yr target of $7.50 (implying +39% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -11.5%) — path to GAAP profitability is the core thesis risk. Down 38% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $7.50 (6-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $10.86 — requires the platform / technology to reach commercial scale. 10 yr $28.26 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.